Investigator

Annie Cristhine Moraes Sousa Squiavinato

Senior Postdoctoral Fellow · Brazilian National Cancer Institute

ACMAnnie Cristhine M…
Papers(1)
Osteopontin-c gene ex…
Collaborators(7)
ERP GimbaG Nestal de MoraesLuciana Bueno FerreiraLuciana da Torre Carn…Mariana BoroniMariana Concentino Me…Alessandra Serain
Institutions(4)
Unknown InstitutionUniversidade Federal …Universidade Federal …Instituto Nacional de…

Papers

Osteopontin-c gene expression and subcellular localization in ovarian cancer cells: Implications for prognosis and therapeutic responses

Background Osteopontin is a glycophosphoprotein aberrantly expressed in several tumor types, which exhibits several isoforms generated by post-translational and post-transcriptional mechanisms, including alternative splicing. Among total osteopontin (tOPN), the osteopontin-c (OPN-c) splice variant has been the most explored with an oncogenic role described for a range of tumor types. Especially in ovarian cancer (OC) cells, OPN-c is found overexpressed, presenting both diagnostic and prognostic implications. Objective In this review article, we aim to outline OPN-c roles in cancer, particularly in OC, in which it has been reported as a diagnostic biomarker. Methods We used PubMed search, and experimental procedures were summarized at the Figure legends. Results We identified cytoplasmic, perinuclear, and nuclear OPN-c in OC cells that overexpress this OPN splice variant. Moreover, we report that OPN-c splicing isoform is found highly expressed in endometrioid OC patients’ samples, compared to non-neoplastic ovarian tissues. Also, OPN-c expression levels have been associated with worse overall survival and worse progression-free survival in patients with both endometrioid and serous OC. Furthermore, OPN-c may be involved in a wide range of tumor features evoked by signaling pathways, such as AKT, ERK, and FAK. Conclusions Therefore, a better comprehension of OPN-c roles in OC can further contribute to its application as a biomarker as well as a target for putative treatment strategies, especially those aiming to sensitize tumor cells to chemotherapeutic agents currently used in the OC treatment.

14Works
1Papers
7Collaborators
Ovarian NeoplasmsPrognosisBiomarkers, Tumor

Positions

2026–

Senior Postdoctoral Fellow

Brazilian National Cancer Institute

Education

2026

Post-Doctoral

Wellcome Sanger Institute · Cancer Ageing and Somatic Mutation programme

2025

Post-Doctoral

Instituto Nacional de Câncer

2019

Ph.D. in Oncology (emphasis on cell biology)

Instituto Nacional do Câncer

2014

M.Sc. in Pathology

Universidade Estadual Paulista (Unesp)

2010

Under graduation in Biomedicine (Medical Biology)

Universidade Federal de Goiás

Country

BR

Links & IDs
0000-0003-0345-1571

Scopus: 56728868300